Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
EVO101 · 2 trials · 2 indications
EASI assesses the extent and severity of atopic dermatitis. EASI is a composite index with scores ranging from 0 to 72. Higher values indicate more severe or extensive disease.
The change in the total HS lesion count will be assessed at Week 4, Week 8, and Week 12. The percent change from Baseline will be calculated.
| Arm | Type | Description |
|---|---|---|
| EVO101 Cream | EXPERIMENTAL | Active Treatment, BID, 8 weeks |
| Vehicle Cream | PLACEBO_COMPARATOR | Vehicle Treatment, BID, 8 weeks |
| Open label EVO101 topical cream 0.1% | EXPERIMENTAL | All eligible subjects will receive open label EVO101 topical cream 0.1% |
| Name | Type | Description |
|---|---|---|
| EVO101 | DRUG | Topical Cream |
Inclusion Criteria: 1. Males or non-pregnant, non-lactating females, age 18 years or older 2. Chronic atopic dermatitis for at least 1 year 3. IGA score of 2 or 3 4. BSA of AD involvement of 4-12% 5. EASI of 5-20 Exclusion Criteria: 1. Significant AD flare with 4 weeks 2. Use of biologic therapy ...
EVO101 is an investigational topical cream being studied for atopic dermatitis (eczema) and hidradenitis suppurativa (HS). It is a small molecule developed by Evommune, Inc. for dermatological conditions. EVO101 is not FDA approved and remains in clinical development.
EVO101 is developed by Evommune, Inc., a biopharmaceutical company. The company is advancing EVO101 as a topical cream for atopic dermatitis and hidradenitis suppurativa. Evommune, Inc. is the sponsor of clinical trials evaluating EVO101.
EVO101 is in Phase 2 clinical development for atopic dermatitis, with a completed Phase 2 trial. It is also being studied in an early Phase 1 trial for hidradenitis suppurativa. EVO101 is investigational and not yet approved by regulatory authorities.
EVO101 has two clinical trials. NCT05579899 is a completed Phase 2 study of EVO101 topical cream in atopic dermatitis with 119 participants. NCT06645821 is a recruiting early Phase 1 trial of EVO101 0.1% topical cream in mild to moderate hidradenitis suppurativa with 15 participants.
EVO101 is not FDA approved. It is an investigational drug currently in clinical trials for atopic dermatitis and hidradenitis suppurativa. The Phase 2 trial for atopic dermatitis has been completed, and an early Phase 1 trial for hidradenitis suppurativa is recruiting participants.